Silence Therapeutics PLC PDMR Shareholding (3659O)
May 29 2020 - 3:37AM
UK Regulatory
TIDMSLN
RNS Number : 3659O
Silence Therapeutics PLC
29 May 2020
PDMR Shareholding
May 29, 2020
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the
Company") a leader in the discovery, development and delivery of
novel RNA therapeutics for the treatment of serious diseases, today
announces that on May 28th 15,800 Shares were purchased by Iain
Ross, Executive Chairman of the Company, through his SIPP at
GBP4.70 per share.
Following this purchase, Iain Ross is interested in 44,693
ordinary shares (0.05%) of the issued shared capital of the
Company. The previously disclosed 25,000 shares held by Mr Ross did
not include 3,893 shares that were already held in Mr Ross's SIPP
and originate from his previous tenure with the Company that ended
in 2010. The 44,693 ordinary shares now held by Mr Ross corrects
for these previously undisclosed shares.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Iain Ross
--------------------------- --------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position / status Executive Chairman
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- --------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- --------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- --------------------------------------------
c) Prices(a) and volume(s) Price Volume
GBP4.70 15,800
-------
--------------------------- --------------------------------------------
d) Aggregated information
- Aggregated volume 15,800 Ordinary Shares
- Price GBP74,260.00
--------------------------- --------------------------------------------
e) Date of the transaction 28 May 2020
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------- --------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Iain Ross, Executive Chairman 6900
Dr Rob Quinn, Chief Financial Officer
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-associated proteins. Silence's proprietary
RNA chemistries and delivery systems are designed to improve the
stability of molecules and enhance effective delivery to target
cells, providing a powerful modular technology well suited to
tackle life-threatening diseases. The Company has secured high
value research and collaboration agreements with AstraZeneca,
Mallinckrodt Pharmaceuticals and Takeda. For more information,
please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFZGZKRLKGGZG
(END) Dow Jones Newswires
May 29, 2020 04:37 ET (08:37 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024